Company Overview of Exeltis USA Dermatology, LLC
Exeltis USA Dermatology, LLC discovers, develops, produces, and markets medicinal products to improve the life of people worldwide. It offers a range of products that includes products for therapeutic areas, such as women’s health, respiratory, dermatology, cardiology, central nervous system, ophthalmology, oncology, gastroenterology, infectious diseases and endocrinology, and others. It offers products for women at various stages of life (contraception, pregnancy, fertility, and menopause), a portfolio of gynecological products to meet women’s reproductive health needs, treat associated conditions, and improve female wellbeing and quality of life; a range of oral and inhalation medicines; a...
411 South State Street
Newtown, PA 18940
Founded in 2003
Key Executives for Exeltis USA Dermatology, LLC
Co-founder, Chief Executive Officer, President and Director
Vice President of Finance
Vice President of Quality Assurance, Regulatory Compliance & Regulator Affairs
Compensation as of Fiscal Year 2014.
Exeltis USA Dermatology, LLC Key Developments
Quinnova Pharmaceuticals, LLC has Changed its Name to Exeltis USA Dermatology, LLC
Oct 31 14
Quinnova Pharmaceuticals, LLC changed its name to Exeltis USA Dermatology, LLC.
Quinnova Pharmaceuticals LLC Announces Launch of ECOZA(TM) Topical Foam, 1%
Mar 18 14
Quinnova Pharmaceuticals LLC announced the launch of its recently U.S. Food and Drug Administration approved ECOZA(TM) (econazole nitrate) topical foam, 1%. ECOZA(TM) FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. ECOZA(TM) FOAM, a novel alternative for the treatment of interdigital tinea pedis (athletes foot between the toes), combines the proven antifungal efficacy of econazole nitrate with the skin-restoring properties of Proderm Technology(R). Proven to kill fungi that cause interdigital tinea pedis when applied once-daily for 4 weeks, its unique, alcohol-free foam delivery helps protect and restore skin, penetrating quickly and drying rapidly without the greasy residue that is common among other creams and gels. ECOZA(TM) FOAM is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. ECOZA(TM) FOAM should be applied to cover affected areas once daily for 4 weeks. ECOZA(TM) FOAM is for topical use only and is not for oral, ophthalmic, or intravaginal use. In two double-blind, parallel-group, vehicle-controlled, multicenter clinical trials, 495 subjects aged >=12 years with a clinical diagnosis of interdigital tinea pedis and fungal culture positive for a dermatophyte at baseline received ECOZA(TM) FOAM (n=246) or foam vehicle (n=249). Subjects applied ECOZA(TM) FOAM or foam vehicle once-daily for 4 weeks. The primary endpoint was proportion of subjects who achieved a complete cure (negative KOH, negative fungal culture, no evidence of clinical disease as indicated by complete resolution of all signs and symptoms) at 2 weeks post-treatment (Day 43). Secondary endpoints included mycologic cure (negative KOH and negative culture) and effective treatment (mycologic cure + no or mild erythema and/or scaling and all other signs and symptoms absent). The results from the clinical studies demonstrated that ECOZA(TM) FOAM exhibited superiority over foam vehicle for the primary and secondary endpoints and demonstrated potent antifungal activity against all of the pathogens evaluated with a high mycologic cure rate. The complete cure rate at Day 43 (2 weeks post-treatment) was higher in the ECOZA(TM) FOAM group (24.3%) than in the foam vehicle group (3.6%). In addition, higher rates of mycologic cure (67.6% vs 16.9%) and effective treatment (48.6% vs 10.8%) were observed with econazole nitrate foam 1% vs the foam vehicle. ECOZA(TM) FOAM was safe and well tolerated with a safety profile comparable with the foam vehicle. During clinical trials with ECOZA(TM) FOAM the most common adverse reactions were application site reactions, which occurred in less than 1% of subjects in both the ECOZA(TM) FOAM and vehicle arms. Click for full prescribing information.
Suneva Medical, Inc. Selects Quinnova Pharmaceuticals LLC to Co-Promote ReFissa
Jun 4 13
Suneva Medical, Inc. announced that it has selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin. The relationship will expand the awareness and prescriber base of ReFissa in the U.S. dermatology community.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|